BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 30794953)

  • 1. The impact of HCG in IVF Treatment: Does it depend on age or on protocol?
    Theofanakis C; Athanasiou V; Liokari E; Stavrou S; Sakellariou M; Athanassiou AI; Athanassiou A; Drakakis P; Loutradis D
    J Gynecol Obstet Hum Reprod; 2019 May; 48(5):341-345. PubMed ID: 30794953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Follicular Phase Human Chorionic Gonadotropin Addition May Improve the Outcomes of
    Zhang C; Wu F; Wu Z; Sun B; Chen C; Qian W
    Front Endocrinol (Lausanne); 2021; 12():739773. PubMed ID: 34707571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Triggering With Gonadotropin-Releasing Hormone Agonist and Standard Dose Human Chorionic Gonadotropin in Patients With a High Immature Oocyte Rate.
    Fabris AM; Cruz M; Legidos V; Iglesias C; Muñoz M; García-Velasco JA
    Reprod Sci; 2017 Aug; 24(8):1221-1225. PubMed ID: 28715965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
    Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
    Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
    Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
    J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of low-dose hCG to rFSH during ovarian stimulation for IVF/ICSI: is it beneficial?
    Partsinevelos GA; Antonakopoulos N; Kallianidis K; Drakakis P; Anagnostou E; Bletsa R; Loutradis D
    Clin Exp Obstet Gynecol; 2016; 43(6):818-825. PubMed ID: 29944230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization.
    Avrech OM; Orvieto R; Pinkas H; Sapir-Rufas O; Feldberg D; Fisch B
    Gynecol Endocrinol; 2004 Nov; 19(5):247-52. PubMed ID: 15726912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial.
    Kyrou D; Kolibianakis EM; Fatemi HM; Tarlatzis BC; Tournaye H; Devroey P
    Fertil Steril; 2011 Nov; 96(5):1112-5. PubMed ID: 21924414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
    Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
    Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
    Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
    Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.